Civallero Monica, Schroers-Martin Joseph G, Horwitz Steven, Manni Martina, Stepanishyna Yana, Cabrera Maria Elena, Vose Julie, Spina Michele, Hitz Felicitas, Nagler Arnon, Montoto Silvia, Chiattone Carlos, Skrypets Tetiana, Perez Saenz M Angeles, Priolo Giorgio, Luminari Stefano, Lymboussaki Athina, Pavlovsky Astrid, Marino Dario, Liberati Marina, Trotman Judith, Mannina Donato, Federico Massimo, Advani Ranjana
CHIMOMO Department, University of Modena and Reggio Emilia, Modena, Italy.
Division of Oncology, Department of Medicine, Stanford University, Stanford, California, USA.
Br J Haematol. 2024 Jul;205(1):166-174. doi: 10.1111/bjh.19433. Epub 2024 Mar 26.
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of haematological cancers with generally poor clinical outcomes. However, a subset of patients experience durable disease control, and little is known regarding long-term outcomes. The International T-cell Lymphoma Project (ITCLP) is the largest prospectively collected cohort of patients with PTCLs, providing insight into clinical outcomes at academic medical centres globally. We performed a long-term outcome analysis on patients from the ITCLP with available 10-year follow-up data (n = 735). The overall response rate to first-line therapy was 68%, while 5- and 10-year overall survival estimates were 49% and 40% respectively. Most deaths occurred prior to 5 years, and for patients alive at 5 years, the chance of surviving to 10 years was 84%. However, lymphoma remained the leading cause of death in the 5- to 10-year period (67%). Low-risk International Prognostic Index and Prognostic Index for T-cell lymphoma scores both identified patients with improved survival, while in multivariate analysis, age >60 years and Eastern Cooperative Oncology Group performance status 2-4 were associated with inferior outcomes. The favourable survival seen in patients achieving durable initial disease control emphasizes the unmet need for optimal front-line therapeutic approaches in PTCLs.
外周T细胞淋巴瘤(PTCLs)是一组异质性血液系统癌症,临床结局总体较差。然而,有一部分患者实现了持久的疾病控制,而关于长期结局的了解却很少。国际T细胞淋巴瘤项目(ITCLP)是前瞻性收集的最大的PTCLs患者队列,为全球学术医疗中心的临床结局提供了见解。我们对ITCLP中具有10年随访数据的患者(n = 735)进行了长期结局分析。一线治疗的总缓解率为68%,而5年和10年总生存率估计分别为49%和40%。大多数死亡发生在5年之前,对于存活5年的患者,存活至10年的几率为84%。然而,淋巴瘤在5至10年期间仍然是主要死因(67%)。低风险国际预后指数和T细胞淋巴瘤预后指数均识别出存活期改善的患者,而在多变量分析中,年龄>60岁和东部肿瘤协作组体能状态2 - 4与较差的结局相关。在实现初始疾病持久控制的患者中观察到的良好生存情况强调了PTCLs中对最佳一线治疗方法的未满足需求。